Jessica Tassan
Stock Analyst at Piper Sandler
(0.97)
# 3,972
Out of 5,182 analysts
87
Total ratings
27.03%
Success rate
-14.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jessica Tassan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVS CVS Health | Maintains: Overweight | $101 → $99 | $77.30 | +28.07% | 7 | Mar 31, 2026 | |
| CI The Cigna Group | Reiterates: Overweight | $374 → $370 | $278.64 | +32.79% | 5 | Mar 3, 2026 | |
| TDOC Teladoc Health | Reiterates: Overweight | $12 → $9 | $5.69 | +58.17% | 7 | Feb 26, 2026 | |
| DOCS Doximity | Maintains: Overweight | $40 → $42 | $24.71 | +69.97% | 6 | Feb 20, 2026 | |
| OMCL Omnicell | Reiterates: Overweight | $63 → $49 | $38.28 | +28.00% | 5 | Feb 6, 2026 | |
| HNGE Hinge Health | Maintains: Overweight | $71 → $60 | $43.32 | +38.50% | 3 | Jan 9, 2026 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $20 → $30 | $21.22 | +41.38% | 6 | Jan 6, 2026 | |
| OSCR Oscar Health | Upgrades: Overweight | $13 → $25 | $15.79 | +58.33% | 7 | Nov 26, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $423 → $417 | $324.63 | +28.45% | 9 | Oct 29, 2025 | |
| PHR Phreesia | Maintains: Overweight | $33 → $34 | $9.17 | +270.77% | 6 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $2.84 | +533.80% | 4 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.32 | +203.03% | 12 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $86 | $20.59 | +317.68% | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $288 → $272 | $205.14 | +32.59% | 4 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 → $8 | $6.12 | +30.72% | 3 | May 23, 2025 |
CVS Health
Mar 31, 2026
Maintains: Overweight
Price Target: $101 → $99
Current: $77.30
Upside: +28.07%
The Cigna Group
Mar 3, 2026
Reiterates: Overweight
Price Target: $374 → $370
Current: $278.64
Upside: +32.79%
Teladoc Health
Feb 26, 2026
Reiterates: Overweight
Price Target: $12 → $9
Current: $5.69
Upside: +58.17%
Doximity
Feb 20, 2026
Maintains: Overweight
Price Target: $40 → $42
Current: $24.71
Upside: +69.97%
Omnicell
Feb 6, 2026
Reiterates: Overweight
Price Target: $63 → $49
Current: $38.28
Upside: +28.00%
Hinge Health
Jan 9, 2026
Maintains: Overweight
Price Target: $71 → $60
Current: $43.32
Upside: +38.50%
Alignment Healthcare
Jan 6, 2026
Maintains: Overweight
Price Target: $20 → $30
Current: $21.22
Upside: +41.38%
Oscar Health
Nov 26, 2025
Upgrades: Overweight
Price Target: $13 → $25
Current: $15.79
Upside: +58.33%
UnitedHealth Group
Oct 29, 2025
Maintains: Overweight
Price Target: $423 → $417
Current: $324.63
Upside: +28.45%
Phreesia
Sep 5, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $9.17
Upside: +270.77%
Aug 28, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $2.84
Upside: +533.80%
Aug 27, 2025
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.32
Upside: +203.03%
Aug 15, 2025
Maintains: Overweight
Price Target: $44 → $86
Current: $20.59
Upside: +317.68%
Jul 31, 2025
Maintains: Neutral
Price Target: $288 → $272
Current: $205.14
Upside: +32.59%
May 23, 2025
Reiterates: Neutral
Price Target: $10 → $8
Current: $6.12
Upside: +30.72%